|Dr. Garo H. Armen||Co-Founder & Exec. Chairman||N/A||N/A||1953|
|Dr. Alexander K. Arrow C.F.A., M.D., CFA||CFO, Compliance Officer & Sec.||125k||N/A||1971|
|Dr. Dalia Barsyte||Chief Technology Advisor||N/A||N/A||N/A|
|Dr. David A. Lovejoy||Chief Scientific Officer||N/A||N/A||N/A|
|Dr. Robert B. Stein||Chief Scientific Advisor & Director||N/A||N/A||1951|
Protagenic Therapeutics, Inc. engages in the discovery and development of therapeutics to treat central nervous system disorders. Its lead drug candidate is PT00114, which is in clinical proof-of-concept studies for the treatment-resistant depression and/or post-traumatic stress disorder. The company is based in New York, New York.
Protagenic Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.